HC
HCWB.US HCW Biologics Inc
- Market cap
- USD 1.73M
- P/E
- -
- P/B
- 0.23x
- ROE
- -29.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is HCWB.US undervalued?
Graham numberThe Graham number of HCW Biologics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HCW Biologics Inc fundamental analysis
No fundamental analysis for HCW Biologics Inc yet.
HCW Biologics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patie…
Full company profileHCW Biologics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HCW Biologics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 4.10M | 4.10M | 6.72M | 2.84M | 2.57M | 54.2K | 13.4M |
| Gross Profit | -422K | 4.10M | -544K | 2.59M | 560K | 959K | 10.8K | 12.9M |
| Operating Income | -7.37M | -5.82M | -13.4M | -15.1M | -25.7M | -29.5M | -11.3M | 139K |
| EBITDA | -6.87M | -5.25M | -12.3M | -14.1M | -23.6M | -27.7M | -5.67M | -2.27M |
| Net Income | -7.29M | -5.78M | -12.9M | -14.9M | -25.0M | -30.0M | -7.96M | -2.17M |
| EPS | -1.19 | -0.94 | -0.36 | -2.50 | -4.17 | -4.64 | -23 | -6.21 |
| Balance Sheet | ||||||||
| Total Assets | 10.1M | 15.4M | 53.5M | 46.8M | 28.5M | 30.2M | 24.5M | 26.8M |
| Total Liabilities | 1.07M | 1.00M | 2.32M | 9.38M | 15.1M | 37.0M | 21.8M | 19.3M |
| Shareholders' Equity | 9.00M | 14.4M | 51.2M | 37.4M | 13.5M | -6.77M | 2.76M | 7.43M |
| Cash & Short-term Investments | 7.36M | 8.46M | 36.7M | 32.1M | 3.60M | 4.67M | 1.95M | 741K |
| Total Debt | - | 567K | - | 6.41M | 6.30M | 13.7M | 6.81M | 6.56M |
| Cash Flow | ||||||||
| Operating Cash Flow | -6.77M | -10.4M | -11.0M | -10.4M | -22.5M | -14.2M | -13.4M | -11.1M |
| Capital Expenditure | 1.46M | 187K | 47.3K | 10.3M | 6.20M | 262K | 3.00 | 16.00 |
| Free Cash Flow | -8.23M | -10.6M | -11.0M | -20.7M | -28.7M | -14.5M | -13.4M | -11.1M |
| Ratios | ||||||||
| ROE | -81.0% | -40.1% | -25.1% | -39.8% | -185.7% | - | -287.9% | -29.3% |
| ROA | -72.5% | -37.5% | -24.0% | -31.8% | -87.7% | -99.3% | -32.5% | -8.1% |
| Net Profit Margin | - | -141.0% | -313.7% | -221.7% | -879.5% | -1,169.7% | -14,677.1% | -16.3% |
| Debt to Equity | - | 0.04x | - | 0.17x | 0.47x | - | 2.46x | 0.88x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HCW Biologics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 2.82M | 0.08 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:6 on Jun 30, 2026.
Who owns HCW Biologics Inc
- Insiders 7.98%
- Institutions 8.37%
- Public & others 83.65%
- Shares outstanding 2.24M
- Free float 1.68M
Top funds holding HCWB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 9.32K | 0.42% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.20K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 121.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding HCWB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 52.1K | 0.39% | +2,112.99% | Jun 2026 |
| Citadel Advisors Llc | 19.9K | 0.15% | +358.75% | Jun 2026 |
| HRT FINANCIAL LLC | 13.6K | 0.10% | -69.41% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 6.51K | 0.05% | +1,953.63% | Jun 2026 |
| Tower Research Capital LLC | 4.12K | 0.03% | +66.48% | Jun 2026 |
| Connective Capital Management LLC | 3.34K | 0.02% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.00K | 0.01% | -0.05% | Jun 2026 |
| Golden State Wealth Management, LLC | 1.67K | 0.01% | 0.00% | Jun 2026 |
| Barclays PLC | 191.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 11.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 4.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 1.00 | 0.00% | -99.93% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Virtu Financial LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 0.00 | 0.00% | 0.00% | Jun 2026 |
HCW Biologics Inc company profile
- Company name
- HCW Biologics Inc
- Ticker
- HCWB.US
- Exchange
- USA Stocks
- Listed since
- Jul 20, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Fiscal year end
- December
- Address
- 2929 North Commerce Parkway, Miramar, FL, United States, 33025
- Phone
- 954 842 2024
- Website
- hcwbiologics.com
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
HCW Biologics Inc management
5- Dr. Hing C. Wong Ph.D.Founder, CEO, Director & Secretary · born 1954
- Ms. Rebecca Byam CPA, M.B.A.Chief Financial Officer · born 1956
- Dr. Peter Rhode Ph.D.Chief Scientific Officer & VP of Clinical Operations · born 1958
- Ms. Nicole Valdivieso Esq., J.D.Vice President of Legal Affairs
- Mr. Lee D. FlowersSenior Vice President of Business Development · born 1946